Should myeloid and lymphoid neoplasms with <i><scp>PCM</scp>1‐<scp>JAK</scp>2</i> and other rearrangements of <i><scp>JAK</scp>2</i> be recognized as specific entities?
Summary Since the publication of the 2001 and 2008 World Health Organization classifications of tumours of haematopoietic and lymphoid tissues, there has been an increasing move...